In two-way race with Novartis, Merck scores first regulatory approval for targeted lung cancer drug
In the two-man race to develop a new inhibitor for an aggressive form of lung cancer, Merck KGaA has won the first regulatory approval.
Japan became the first country to approve the pharma giant’s MET inhibitor tepotinib, the first targeted pill for the 3 to 4% of non-small lung cancer patients with a MET mutation. In a Phase II study published last year in Clinical Oncology, just over half of the 89 patients responded to the treatment. The response lasted for a median of 9.8 months.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.